2. Academic Validation
  3. PI3K/Akt inhibition promotes AR activity and prostate cancer cell proliferation through p35-CDK5 modulation

PI3K/Akt inhibition promotes AR activity and prostate cancer cell proliferation through p35-CDK5 modulation

  • Biochim Biophys Acta Mol Basis Dis. 2025 Feb;1871(2):167568. doi: 10.1016/j.bbadis.2024.167568.
Wei-Hsiang Kao 1,  Kun-Yuan Chiu 2,  Stella Chin-Shaw Tsai 3,  Chieh-Lin Jerry Teng 4,  Muhammet Oner 5,  Chih-Ho Lai 6,  Jer-Tsong Hsieh 7,  Chi-Chien Lin 8,  Hsin-Yi Wang 9,  Mei-Chih Chen 10,  Ho Lin 11
Affiliations

Affiliations

  • 1 Department of Life Sciences, National Chung Hsing University, Taichung 40227, Taiwan; Translational Cell Therapy Center, China Medical University Hospital, Taichung 40447, Taiwan. Electronic address: d106052004@mail.nchu.edu.tw.
  • 2 Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung 40705, Taiwan.
  • 3 Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 40227, Taiwan; Superintendent Office, Tungs' Taichung MetroHarbor Hospital, Taichung, Taiwan; College of Life Sciences, National Chung Hsing University, Taichung 40227, Taiwan.
  • 4 Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 40227, Taiwan; Division of Hematology/Medical Oncology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan. Electronic address: drteng@vghtc.gov.tw.
  • 5 Department of Life Sciences, National Chung Hsing University, Taichung 40227, Taiwan. Electronic address: muhammet.oner053@gmail.com.
  • 6 Department of Microbiology and Immunology, Chang Gung University, Taoyuan 33302, Taiwan. Electronic address: chlai@mail.cgu.edu.tw.
  • 7 Department of Urology, University of Texas Southwestern Medical Center, TX75390, USA. Electronic address: JT.Hsieh@utsouthwestern.edu.
  • 8 Institute of Biomedical Science, National Chung Hsing University, Taichung 40227, Taiwan.
  • 9 Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan. Electronic address: hywang@vghtc.gov.tw.
  • 10 Translational Cell Therapy Center, China Medical University Hospital, Taichung 40447, Taiwan. Electronic address: midyjack@gmail.com.
  • 11 Department of Life Sciences, National Chung Hsing University, Taichung 40227, Taiwan. Electronic address: hlin@dragon.nchu.edu.tw.
PMID: 39536992 DOI: 10.1016/j.bbadis.2024.167568
Abstract

Aberrant PI3K/Akt activation is linked to prostate Cancer (PCa) malignancy, while Androgen Receptor (AR) is critical in early-stage PCa development. Investigating the interaction between these pathways is crucial for PCa malignancy. Our previous study demonstrated that p35-CDK5 mediates post-translational modifications of AR, STAT3, and p21CIP1, eventually promoting PCa cell growth. This study revealed the role of p35-CDK5 in between PI3K/Akt and AR by utilizing LNCaP and 22Rv1 cells. Through the TCGA database analysis, we observed a positive correlation between PTEN and p35 expression, implying a potential negative correlation between PI3K/Akt activation and p35-CDK5. Inhibiting PI3K/Akt with LY294002, Capivasertib (AZD5363), or using an inactive Akt mutant significantly increased p35 expression and subsequently enhanced AR stability and activation in PCa cells. On the Other hand, CDK5-knockdown reversed these effects. The involvement of the β-catenin/Egr1-axis was observed in regulating PI3K/Akt inhibition and p35-CDK5 activation, implying a possible mechanistic connection. Importantly, CDK5 knockdown further reduced PI3K/Akt-inhibition-induced AR and cell viability maintenance, suggesting a compensatory role for CDK5-AR in maintaining cell viability under Akt inhibition. In conclusion, PI3K/Akt inhibition could trigger p35-CDK5-dependent AR activation and cell viability, highlighting p35-CDK5 as a critical link connecting PI3K/Akt inhibition to AR activation and pivotal in PCa cell resistance to PI3K/Akt blockade.

Keywords

AR; Cell viability; PI3K/Akt; Prostate cancer; p35-CDK5.

Figures
Products